Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,totalCashFromFinancingActivities,issuanceOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,ask,bid,regularMarketPreviousClose,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,currency,marketState,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,market,priceHint,exchangeDataDelayedBy,twoHundredDayAverageChangePercent,shortName,exchange,epsCurrentYear,priceEpsCurrentYear,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GLTO,152571000.0,25261800,9990000,,-13345000,,-13345000,3562000,0,-13552000,-13552000,,,,,,0,0,13552000,0,207000,,-13345000,-13345000,270206000.0,6084000.0,152571000.0,457000.0,158655000.0,4224000.0,-117705000.0,70000.0,2181000.0,74253000.0,5540000.0,70000.0,996000.0,116902000.0,38576000.0,36081000.0,1178000.0,1782000.0,-74566000.0,-1069000.0,-74631000.0,-794000.0,-89386000.0,-604000.0,-14151000.0,99000.0,958000.0,-65000.0,,,,111362000.0,en-US,US,EQUITY,True,Delayed Quote,1.1235998,4.42 - 4.5299,0.0,0.0,4.45,8,18,finmb_154090027,NasdaqGS,"Galecto, Inc.",USD,1240284,107028,0.70000005,0.18421054,3.8 - 17.99,-13.49,-0.749861,3.8,17.99,1617015540,1617015540,1617015540,USD,PREPRE,4.5,1630526403,0.05000019,4.46,4.5299,4.42,61002,us_market,4,0,-0.2511757,"Galecto, Inc.",NMS,-2.23,-2.0179372,4.3,0.19999981,0.046511583,6.0094204,-1.5094204,113678096,15,America/New_York,EDT,-14400000,False,False,,,,17.99,3.8,4.3,6.0094,1.24M,107.03k,25.26M,,10.53M,11.42%,60.24%,139.27k,1.69,0.71%,0.55%,121.41k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.90%,-42.29%,,,,,,-42.51M,,,110.33M,4.37,959k,0.63,21.10,,-44.38M,-25.51M,Value,2200,Healthcare,28,"Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 70 52 10,1609372800,Denmark,http://galecto.com,86400,Ole Maaloes Vej 3,Biotechnology,Copenhagen N
t-1,GLTO,165489000.0,25261800,7753000,,-11577000,,-11577000,3549000,0,-11302000,-11302000,,,,,,0,0,11302000,0,-275000,,-11577000,-3929000,269175000.0,6107000.0,165489000.0,343000.0,171596000.0,1862000.0,-104360000.0,674000.0,1416000.0,163582000.0,5566000.0,674000.0,885000.0,169295000.0,,,2209000.0,2851000.0,-74566000.0,-746000.0,-74631000.0,-2776000.0,78262000.0,989000.0,-14517000.0,52000.0,530000.0,-65000.0,91790000.0,88475000.0,-2157000.0,163729000.0,en-US,US,EQUITY,True,Delayed Quote,1.1235998,4.42 - 4.5299,0.0,0.0,4.45,8,18,finmb_154090027,NasdaqGS,"Galecto, Inc.",USD,1240284,107028,0.70000005,0.18421054,3.8 - 17.99,-13.49,-0.749861,3.8,17.99,1617015540,1617015540,1617015540,USD,PREPRE,4.5,1630526403,0.05000019,4.46,4.5299,4.42,61002,us_market,4,0,-0.2511757,"Galecto, Inc.",NMS,-2.23,-2.0179372,4.3,0.19999981,0.046511583,6.0094204,-1.5094204,113678096,15,America/New_York,EDT,-14400000,False,False,,,,17.99,3.8,4.3,6.0094,1.24M,107.03k,25.26M,,10.53M,11.42%,60.24%,139.27k,1.69,0.71%,0.55%,121.41k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.90%,-42.29%,,,,,,-42.51M,,,110.33M,4.37,959k,0.63,21.10,,-44.38M,-25.51M,Value,2200,Healthcare,28,"Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 70 52 10,1609372800,Denmark,http://galecto.com,86400,Ole Maaloes Vej 3,Biotechnology,Copenhagen N
t-2,GLTO,-91737000.0,25261800,7651000,,-11651000,,-11651000,2515000,0,-10166000,-10166000,,,,,,0,0,10166000,0,-1485000,,-11651000,-14364000,1361000.0,8870000.0,-91737000.0,947000.0,98154000.0,3901000.0,-92783000.0,-315000.0,1106000.0,85333000.0,8281000.0,-315000.0,905000.0,96143000.0,,,6909000.0,4463000.0,-74566000.0,2679000.0,-74631000.0,180000.0,49500000.0,2147000.0,-8577000.0,82000.0,133000.0,-65000.0,55930000.0,88475000.0,-2797000.0,87862000.0,en-US,US,EQUITY,True,Delayed Quote,1.1235998,4.42 - 4.5299,0.0,0.0,4.45,8,18,finmb_154090027,NasdaqGS,"Galecto, Inc.",USD,1240284,107028,0.70000005,0.18421054,3.8 - 17.99,-13.49,-0.749861,3.8,17.99,1617015540,1617015540,1617015540,USD,PREPRE,4.5,1630526403,0.05000019,4.46,4.5299,4.42,61002,us_market,4,0,-0.2511757,"Galecto, Inc.",NMS,-2.23,-2.0179372,4.3,0.19999981,0.046511583,6.0094204,-1.5094204,113678096,15,America/New_York,EDT,-14400000,False,False,,,,17.99,3.8,4.3,6.0094,1.24M,107.03k,25.26M,,10.53M,11.42%,60.24%,139.27k,1.69,0.71%,0.55%,121.41k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.90%,-42.29%,,,,,,-42.51M,,,110.33M,4.37,959k,0.63,21.10,,-44.38M,-25.51M,Value,2200,Healthcare,28,"Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 70 52 10,1609372800,Denmark,http://galecto.com,86400,Ole Maaloes Vej 3,Biotechnology,Copenhagen N
t-3,GLTO,-71148000.0,25261800,4707000,,-5674000,,-5674000,1123000,0,-5830000,-5830000,,,,,,0,0,5830000,0,156000,,-5674000,-5674000,1227000.0,3894000.0,-71148000.0,407000.0,40962000.0,2455000.0,-81132000.0,-2646000.0,1060000.0,35843000.0,3505000.0,-2646000.0,496000.0,39406000.0,,,1108000.0,1748000.0,-74566000.0,-2131500.0,-74631000.0,-612000.0,31480000.0,-210000.0,-7978000.0,25000.0,187000.0,-65000.0,39668000.0,88475000.0,-2797000.0,35901000.0,en-US,US,EQUITY,True,Delayed Quote,1.1235998,4.42 - 4.5299,0.0,0.0,4.45,8,18,finmb_154090027,NasdaqGS,"Galecto, Inc.",USD,1240284,107028,0.70000005,0.18421054,3.8 - 17.99,-13.49,-0.749861,3.8,17.99,1617015540,1617015540,1617015540,USD,PREPRE,4.5,1630526403,0.05000019,4.46,4.5299,4.42,61002,us_market,4,0,-0.2511757,"Galecto, Inc.",NMS,-2.23,-2.0179372,4.3,0.19999981,0.046511583,6.0094204,-1.5094204,113678096,15,America/New_York,EDT,-14400000,False,False,,,,17.99,3.8,4.3,6.0094,1.24M,107.03k,25.26M,,10.53M,11.42%,60.24%,139.27k,1.69,0.71%,0.55%,121.41k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-25.90%,-42.29%,,,,,,-42.51M,,,110.33M,4.37,959k,0.63,21.10,,-44.38M,-25.51M,Value,2200,Healthcare,28,"Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",Copenhagen,45 70 70 52 10,1609372800,Denmark,http://galecto.com,86400,Ole Maaloes Vej 3,Biotechnology,Copenhagen N
